NASDAQ:FENC

Fennec Pharmaceuticals Competitors

$6.48
+0.16 (+2.53 %)
(As of 04/14/2021 02:46 PM ET)
Add
Compare
Today's Range
$6.37
Now: $6.48
$6.48
50-Day Range
$5.99
MA: $6.99
$8.31
52-Week Range
$4.80
Now: $6.48
$10.67
Volume2,336 shs
Average Volume101,466 shs
Market Capitalization$168.50 million
P/E RatioN/A
Dividend YieldN/A
Beta0.07

Competitors

Fennec Pharmaceuticals (NASDAQ:FENC) Vs. VXRT, DBVT, HARP, TARS, ATHA, and MGTX

Should you be buying FENC stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Fennec Pharmaceuticals, including Vaxart (VXRT), DBV Technologies (DBVT), Harpoon Therapeutics (HARP), Tarsus Pharmaceuticals (TARS), Athira Pharma (ATHA), and MeiraGTx (MGTX).

Fennec Pharmaceuticals (NASDAQ:FENC) and Vaxart (NASDAQ:VXRT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk.

Profitability

This table compares Fennec Pharmaceuticals and Vaxart's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fennec PharmaceuticalsN/A-84.34%-75.51%
Vaxart-281.50%-84.90%-44.67%

Insider & Institutional Ownership

53.6% of Fennec Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.9% of Vaxart shares are owned by institutional investors. 9.1% of Fennec Pharmaceuticals shares are owned by insiders. Comparatively, 7.3% of Vaxart shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk and Volatility

Fennec Pharmaceuticals has a beta of 0.07, suggesting that its share price is 93% less volatile than the S&P 500. Comparatively, Vaxart has a beta of -0.11, suggesting that its share price is 111% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Fennec Pharmaceuticals and Vaxart, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fennec Pharmaceuticals00303.00
Vaxart00203.00

Fennec Pharmaceuticals currently has a consensus target price of $14.6667, suggesting a potential upside of 127.39%. Vaxart has a consensus target price of $15.00, suggesting a potential upside of 174.73%. Given Vaxart's higher possible upside, analysts clearly believe Vaxart is more favorable than Fennec Pharmaceuticals.

Valuation and Earnings

This table compares Fennec Pharmaceuticals and Vaxart's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fennec PharmaceuticalsN/AN/A$-12,770,000.00($0.64)-10.13
Vaxart$9.86 million65.45$-18,650,000.00($0.86)-6.37

Fennec Pharmaceuticals has higher earnings, but lower revenue than Vaxart. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaxart, indicating that it is currently the more affordable of the two stocks.

Summary

Fennec Pharmaceuticals beats Vaxart on 9 of the 12 factors compared between the two stocks.

Fennec Pharmaceuticals (NASDAQ:FENC) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Profitability

This table compares Fennec Pharmaceuticals and DBV Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fennec PharmaceuticalsN/A-84.34%-75.51%
DBV TechnologiesN/AN/AN/A

Insider and Institutional Ownership

53.6% of Fennec Pharmaceuticals shares are held by institutional investors. Comparatively, 32.5% of DBV Technologies shares are held by institutional investors. 9.1% of Fennec Pharmaceuticals shares are held by company insiders. Comparatively, 15.3% of DBV Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Fennec Pharmaceuticals has a beta of 0.07, suggesting that its stock price is 93% less volatile than the S&P 500. Comparatively, DBV Technologies has a beta of 2.91, suggesting that its stock price is 191% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Fennec Pharmaceuticals and DBV Technologies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fennec Pharmaceuticals00303.00
DBV Technologies23402.22

Fennec Pharmaceuticals presently has a consensus target price of $14.6667, suggesting a potential upside of 127.39%. DBV Technologies has a consensus target price of $7.25, suggesting a potential upside of 10.86%. Given Fennec Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Fennec Pharmaceuticals is more favorable than DBV Technologies.

Valuation & Earnings

This table compares Fennec Pharmaceuticals and DBV Technologies' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fennec PharmaceuticalsN/AN/A$-12,770,000.00($0.64)-10.13
DBV Technologies$14.75 million48.42$-172,020,000.00($2.33)-2.79

Fennec Pharmaceuticals has higher earnings, but lower revenue than DBV Technologies. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Summary

DBV Technologies beats Fennec Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

Fennec Pharmaceuticals (NASDAQ:FENC) and Harpoon Therapeutics (NASDAQ:HARP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Valuation & Earnings

This table compares Fennec Pharmaceuticals and Harpoon Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fennec PharmaceuticalsN/AN/A$-12,770,000.00($0.64)-10.13
Harpoon Therapeutics$5.78 million116.19$-55,570,000.00($2.55)-8.13

Fennec Pharmaceuticals has higher earnings, but lower revenue than Harpoon Therapeutics. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Harpoon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and target prices for Fennec Pharmaceuticals and Harpoon Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fennec Pharmaceuticals00303.00
Harpoon Therapeutics00803.00

Fennec Pharmaceuticals presently has a consensus target price of $14.6667, suggesting a potential upside of 127.39%. Harpoon Therapeutics has a consensus target price of $31.75, suggesting a potential upside of 51.41%. Given Fennec Pharmaceuticals' higher possible upside, equities research analysts clearly believe Fennec Pharmaceuticals is more favorable than Harpoon Therapeutics.

Profitability

This table compares Fennec Pharmaceuticals and Harpoon Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fennec PharmaceuticalsN/A-84.34%-75.51%
Harpoon Therapeutics-434.74%-68.32%-29.45%

Volatility and Risk

Fennec Pharmaceuticals has a beta of 0.07, suggesting that its stock price is 93% less volatile than the S&P 500. Comparatively, Harpoon Therapeutics has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500.

Insider and Institutional Ownership

53.6% of Fennec Pharmaceuticals shares are held by institutional investors. Comparatively, 79.0% of Harpoon Therapeutics shares are held by institutional investors. 9.1% of Fennec Pharmaceuticals shares are held by company insiders. Comparatively, 34.9% of Harpoon Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Harpoon Therapeutics beats Fennec Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

Tarsus Pharmaceuticals (NASDAQ:TARS) and Fennec Pharmaceuticals (NASDAQ:FENC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, institutional ownership, profitability, analyst recommendations and valuation.

Institutional and Insider Ownership

53.6% of Fennec Pharmaceuticals shares are held by institutional investors. 9.1% of Fennec Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Tarsus Pharmaceuticals and Fennec Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tarsus PharmaceuticalsN/AN/AN/A
Fennec PharmaceuticalsN/A-84.34%-75.51%

Earnings and Valuation

This table compares Tarsus Pharmaceuticals and Fennec Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tarsus PharmaceuticalsN/AN/AN/AN/AN/A
Fennec PharmaceuticalsN/AN/A$-12,770,000.00($0.64)-10.13

Analyst Ratings

This is a summary of current ratings and price targets for Tarsus Pharmaceuticals and Fennec Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tarsus Pharmaceuticals00413.20
Fennec Pharmaceuticals00303.00

Tarsus Pharmaceuticals presently has a consensus target price of $37.25, suggesting a potential upside of 21.89%. Fennec Pharmaceuticals has a consensus target price of $14.6667, suggesting a potential upside of 127.39%. Given Fennec Pharmaceuticals' higher possible upside, analysts plainly believe Fennec Pharmaceuticals is more favorable than Tarsus Pharmaceuticals.

Summary

Tarsus Pharmaceuticals beats Fennec Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

Athira Pharma (NASDAQ:ATHA) and Fennec Pharmaceuticals (NASDAQ:FENC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

Insider & Institutional Ownership

66.7% of Athira Pharma shares are held by institutional investors. Comparatively, 53.6% of Fennec Pharmaceuticals shares are held by institutional investors. 9.1% of Fennec Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Athira Pharma and Fennec Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Athira PharmaN/AN/AN/A
Fennec PharmaceuticalsN/A-84.34%-75.51%

Valuation & Earnings

This table compares Athira Pharma and Fennec Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Athira PharmaN/AN/A$-5,160,000.00N/AN/A
Fennec PharmaceuticalsN/AN/A$-12,770,000.00($0.64)-10.13

Analyst Recommendations

This is a breakdown of recent recommendations for Athira Pharma and Fennec Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Athira Pharma00403.00
Fennec Pharmaceuticals00303.00

Athira Pharma currently has a consensus price target of $42.50, suggesting a potential upside of 143.83%. Fennec Pharmaceuticals has a consensus price target of $14.6667, suggesting a potential upside of 127.39%. Given Athira Pharma's higher possible upside, equities research analysts clearly believe Athira Pharma is more favorable than Fennec Pharmaceuticals.

Summary

Athira Pharma beats Fennec Pharmaceuticals on 6 of the 7 factors compared between the two stocks.

MeiraGTx (NASDAQ:MGTX) and Fennec Pharmaceuticals (NASDAQ:FENC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Analyst Recommendations

This is a summary of current ratings and price targets for MeiraGTx and Fennec Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MeiraGTx00403.00
Fennec Pharmaceuticals00303.00

MeiraGTx presently has a consensus target price of $33.00, suggesting a potential upside of 139.13%. Fennec Pharmaceuticals has a consensus target price of $14.6667, suggesting a potential upside of 127.39%. Given MeiraGTx's higher probable upside, analysts clearly believe MeiraGTx is more favorable than Fennec Pharmaceuticals.

Insider & Institutional Ownership

56.4% of MeiraGTx shares are owned by institutional investors. Comparatively, 53.6% of Fennec Pharmaceuticals shares are owned by institutional investors. 16.5% of MeiraGTx shares are owned by company insiders. Comparatively, 9.1% of Fennec Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares MeiraGTx and Fennec Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MeiraGTx$13.29 million45.76$-54,750,000.00($1.65)-8.33
Fennec PharmaceuticalsN/AN/A$-12,770,000.00($0.64)-10.13

Fennec Pharmaceuticals has lower revenue, but higher earnings than MeiraGTx. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

MeiraGTx has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. Comparatively, Fennec Pharmaceuticals has a beta of 0.07, indicating that its share price is 93% less volatile than the S&P 500.

Profitability

This table compares MeiraGTx and Fennec Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MeiraGTx-283.20%-29.14%-17.49%
Fennec PharmaceuticalsN/A-84.34%-75.51%

Summary

MeiraGTx beats Fennec Pharmaceuticals on 8 of the 12 factors compared between the two stocks.


Fennec Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Vaxart logo
VXRT
Vaxart
1.3$5.48+0.7%$650.07 million$9.86 million-9.29
DBV Technologies logo
DBVT
DBV Technologies
1.0$6.50+9.4%$647.15 million$14.75 million-2.79Increase in Short Interest
Gap Down
Harpoon Therapeutics logo
HARP
Harpoon Therapeutics
1.5$20.72+4.2%$643.68 million$5.78 million-9.73Insider Selling
Increase in Short Interest
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.3$30.67+0.4%$631.08 millionN/A0.00Lockup Expiration
News Coverage
Athira Pharma logo
ATHA
Athira Pharma
2.2$17.44+3.1%$627.33 millionN/A0.00Analyst Upgrade
Gap Down
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.74+1.0%$601.99 million$13.29 million-9.74
Compugen logo
CGEN
Compugen
1.4$8.59+1.5%$596.62 million$17.80 million-23.22Analyst Report
News Coverage
Agenus logo
AGEN
Agenus
1.6$2.69+0.7%$554.70 million$150.05 million-2.47News Coverage
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.8$9.09+2.0%$553.38 millionN/A-1.33
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.0$21.24+1.1%$544.11 millionN/A-6.12Gap Down
Solid Biosciences logo
SLDB
Solid Biosciences
1.8$5.30+6.6%$529.05 millionN/A-2.57Increase in Short Interest
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$8.69+1.4%$488.37 million$22.24 million-4.32Increase in Short Interest
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$5.17+1.0%$454.86 millionN/A-8.08Increase in Short Interest
AVROBIO logo
AVRO
AVROBIO
1.7$11.25+5.3%$443.27 millionN/A-3.41
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.6$12.16+5.3%$436.22 millionN/A0.00Analyst Report
Gap Up
Opthea logo
OPT
Opthea
1.5$9.98+3.2%$433.70 millionN/A0.00Lockup Expiration
Gap Down
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$8.90+0.6%$433.23 million$4.36 million-3.11Analyst Downgrade
Gap Up
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.6$9.91+6.7%$419.89 million$147.87 million-3.29Gap Down
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$9.25+1.6%$380.79 millionN/A0.00Analyst Report
News Coverage
Gap Down
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$12.78+2.0%$363.15 millionN/A0.00
Outlook Therapeutics logo
OTLK
Outlook Therapeutics
1.6$1.89+7.4%$352.42 million$8.15 million-1.51Increase in Short Interest
News Coverage
Innate Pharma logo
IPHA
Innate Pharma
1.1$4.38+1.6%$340.45 million$96.12 million-12.88
Cardiff Oncology logo
CRDF
Cardiff Oncology
2.0$8.94+4.3%$321.45 million$250,000.00-3.19Analyst Upgrade
Decrease in Short Interest
Surface Oncology logo
SURF
Surface Oncology
1.4$7.47+2.9%$302.53 million$15.36 million-11.32Analyst Report
Codiak BioSciences logo
CDAK
Codiak BioSciences
1.9$14.56+6.2%$300.44 millionN/A0.00Increase in Short Interest
Lockup Expiration
Gap Down
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.2$5.68+2.3%$290.52 million$2.91 million-1.98
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.8$8.57+3.3%$281.04 millionN/A-3.53News Coverage
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.7$1.89+0.5%$265.61 million$4.13 million-4.20
Cabaletta Bio logo
CABA
Cabaletta Bio
1.6$11.17+2.9%$261.08 millionN/A-8.15Gap Down
ADMA Biologics logo
ADMA
ADMA Biologics
1.6$1.73+1.2%$207.38 million$29.35 million-2.01
LogicBio Therapeutics logo
LOGC
LogicBio Therapeutics
1.3$6.64+3.6%$204.97 millionN/A-4.15Gap Down
Protara Therapeutics logo
TARA
Protara Therapeutics
1.8$17.15+3.2%$186.40 millionN/A0.00Increase in Short Interest
Gap Down
Gamida Cell logo
GMDA
Gamida Cell
1.4$8.13+5.4%$186.25 millionN/A-5.69
Genfit logo
GNFT
Genfit
1.3$4.64+0.4%$179.53 million$45.88 million-2.36
Axcella Health logo
AXLA
Axcella Health
1.6$4.38+6.4%$175.64 millionN/A-2.04News Coverage
Voyager Therapeutics logo
VYGR
Voyager Therapeutics
1.7$4.76+3.4%$173.21 million$104.39 million-2.90
Applied Genetic Technologies logo
AGTC
Applied Genetic Technologies
1.5$4.11+2.4%$171.44 million$2.45 million-1.93News Coverage
INmune Bio logo
INMB
INmune Bio
1.5$11.95+6.1%$167.55 millionN/A-12.32
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
2.0$7.43+2.4%$156.73 millionN/A0.00Increase in Short Interest
Champions Oncology logo
CSBR
Champions Oncology
1.8$11.46+1.0%$153.45 million$32.12 million-88.15
X4 Pharmaceuticals logo
XFOR
X4 Pharmaceuticals
1.8$8.85+4.4%$147.07 millionN/A-2.77Gap Down
ERYTECH Pharma logo
ERYP
ERYTECH Pharma
0.5$6.80+0.3%$144.07 millionN/A-1.73Gap Up
Dyadic International logo
DYAI
Dyadic International
1.3$5.06+1.6%$141.63 million$1.68 million-14.88Increase in Short Interest
Pluristem Therapeutics logo
PSTI
Pluristem Therapeutics
1.4$4.42+0.7%$140.30 million$20,000.000.00
Ayala Pharmaceuticals logo
AYLA
Ayala Pharmaceuticals
1.4$10.50+0.5%$138.29 million$2.33 million0.00
Aziyo Biologics logo
AZYO
Aziyo Biologics
1.4$13.06+0.2%$133.55 millionN/A0.00
Brainstorm Cell Therapeutics logo
BCLI
Brainstorm Cell Therapeutics
1.3$3.56+0.3%$127.52 millionN/A-3.39
TRACON Pharmaceuticals logo
TCON
TRACON Pharmaceuticals
1.7$8.18+2.2%$123.83 million$3 million-2.63Gap Down
Genocea Biosciences logo
GNCA
Genocea Biosciences
1.6$2.45+6.1%$123.09 millionN/A-1.69Analyst Report
News Coverage
Gap Down
La Jolla Pharmaceutical logo
LJPC
La Jolla Pharmaceutical
1.7$4.08+1.5%$110.26 million$23.05 million-1.81
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.